Revisiting BMEZ: Why The Widening Discount Warrants A 'Hold' Rating

The BlackRock Health Sciences Term Trust (BMEZ), a healthcare and biotech closed-end fund, is currently trading at a nearly 10% discount to its Net Asset Value, prompting a 'Hold' assessment. While its 13.74% distribution rate is appealing, it is entirely return of capital, raising sustainability concerns. This, coupled with significant private investments, could further pressure the fund's discount, particularly if distributions are eventually cut.

Analysis

The BlackRock Health Sciences Term Trust (BMEZ), a closed-end fund specializing in healthcare and biotech with a call overwriting strategy, is exhibiting signs of valuation stress despite a high headline yield. The fund's discount to its Net Asset Value (NAV) has widened to approximately 10%, creating a more neutral valuation compared to when the discount was narrower. While the 13.74% distribution rate appears attractive, its composition is a significant red flag, as it is reportedly funded entirely by return of capital (RoC). This indicates the fund is not covering its payout through investment income or realized gains, but rather by returning principal to shareholders, an unsustainable practice that erodes the NAV over time. This risk is compounded by the fund's significant exposure to private investments, which could place further downward pressure on the share price and its discount, especially if management is forced to cut the distribution.

Key Decisions for Investors

• Investors should treat the 13.74% distribution rate with caution, recognizing it is entirely return of capital and not a reflection of the fund's earnings power, posing a significant risk of a future cut.
• For current holders, the widened discount to NAV of nearly 10% may justify a 'Hold' stance, as a valuation buffer now exists, but the position requires close monitoring of NAV performance.
• Potential entry points could emerge if the discount widens further, or if management initiates shareholder-friendly actions to address the valuation gap.